Probiotics for the management of type 2 diabetes mellitus: A systematic review and meta-analysis

Diabetes Research and Clinical Practice

Volumn 118, Issue , 2016, Pages 172-182

  Samah, Syamimi ^a   Ramasamy, Kalavathy ^a   Lim, Siong Meng ^a   Neoh, Chin Fen ^a  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

Glycaemic; Probiotics; Review; Type 2 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 6; MALONALDEHYDE; PLACEBO; PROBIOTIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIFIDOBACTERIUM; CHI SQUARE TEST; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LACTOBACILLUS; MEDICAL RESEARCH; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; STREPTOCOCCUS; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED;

BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; MIDDLE AGED; PROBIOTICS; TREATMENT OUTCOME;

EID: 84977482810     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2016.06.014     Document Type: Article

References (49)

1. [1] Boada, C.A.C., Martinez-Moreno, J.M., Pathophysiology of diabetes mellitus type 2: beyond the duo “insulin resistance-secretion deficit”. Nutr Hosp 28 (2013), 78–87.
2. [2] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35 (2012), 1364–1379.
3. [3] Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U., Shaw, J.E., Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103 (2014), 137–149.
4. [4] Zhang, P., Zhang, X., Brown, J., Vistisen, D., Sicree, R., Shaw, J., et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract, 92, 2010, 301.
5. [5] Panwar, Rashmi, H.M., Batish, V.K., Grover, S., Probiotics as potential biotherapeutics in the management of type 2 diabetes-prospects and perspectives. Diabetes Metab Res Rev 29 (2013), 103–112.
6. [6] Hu, F.B., Manson, J.E., Stampfer, M.J., Colditz, G., Liu, S., Solomon, C.G., et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345 (2001), 790–797.
7. [7] Zhang, Y., Zhang, H., Microbiota associated with type 2 diabetes and its related complications. Food Sci Hum Wellness, 2013, 167–172.
8. [8] Mohamadshahi, M., Veissi, M., Haidari, F., Shahbazian, H., Kaydani, G.-A., Mohammadi, F., Effects of probiotics yogurt consumption on inflammatory biomarkers in patients with type 2 diabetes. BioImpacts 4 (2014), 83–88.
9. [9] Jayashree, B., Bibin, Y.S., Prabhu, D., Shanthirani, C.S., Gokulakrishnan, K., Lakshmi, B.S., et al. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem 388 (2014), 203–210.
10. [10] Khani, S., Hosseini, H.M., Taheri, M., Nourani, M.R., Fooladi, A.A.I., Probiotics an alternative strategy for prevention and treatment of human disease: a review. Inflamm Allery Drug 11 (2012), 79–89.
11. [11] Markets and Markets, Probiotic Ingredients Market by Function (Regular, Preventative, Therapy), Application (Food & Beverage, Dietary Supplements, & Animal Feed), End Use (Human & Animal Probiotics), Ingredient (Bacteria & Yeast), and by Region – Global Trends & Forecast to 2020. 2015 Retrieved 18 February, 2016, from < http://www.marketsandmarkets.com/Market-Reports/probiotic-market-advanced-technologies-and-global-market-69.html>.
12. [12] Shida, K., Sato, T., Iizuka, R., Hoshi, R., Watanabe, O., Igarashi, T., et al. Daily intake of fermented milk with Lactobacillus casei strain Shirota reduces the incidence and duration of upper respiratory tract infections in healthy middle-aged office workers. Eur J Nutr, 2015, 1–9.
13. [13] Kim, E.-H., Hong, H., Hong, K.-S., Choi, K.-S., Han, Y.-M., Kangwan, N., et al. High concentrated probiotics improve inflammatory bowel diseases better than commercial concentration of probiotics. J Food Drug Anal 20 (2012), 292–295.
14. [14] Wong, S., Jamous, A., O'Driscoll, J., Sekhar, R., Weldon, M., Yau, C.Y., et al. A Lactobacillus casei Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial. Br J Nutr 111 (2014), 672–678.
15. [15] Goldin, B.R., Gorbach, S.L., Clinical indications for probiotics: an overview. Clin Infect Dis, 46, 2008.
16. [16] Gomes, A.C., Bueno, A.A., Souza, R.G.M.D., Mota, J.F., Gut microbiota, probiotics and diabetes. Nutr J 13 (2014), 1–13.
17. [17] Carvalho, B.M., Saad, M.J.A., Influence of gut microbiota on subclinical inflammation and insulin resistance. Mediat Inflamm, 2013, 1–13.
18. [18] Ruan, Y., Sun, J., He, J., Chen, F., Chen, R., Chen, H., Effect of probiotics on glycemic control: a systematic review and meta-analysis of randomized, controlled trials. PLoS One, 2015, 10.
19. [19] Higgins, J., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, 2011, The Cochrane Collaboration [updated March 2011].
20. [20] Ejtahed, H., Mohtadi-Nia, J., Homayouni-Rad, A., Niafar, M., Asgari-Jafarabadi, M., Mofid, V., Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 28 (2012), 539–543.
21. [21] Mazloom, Z., Yousefinejad, A., Dabbaghmanesh, M.H., Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress and inflammatory markers in patients with Type 2 Diabetes: a clinical trial. Iran J Med Sci 38 (2013), 38–43.
22. [22] Asemi, Z., Zare, Z., Shakeri, H., Sabihi, S.-S., Esmaillzadeh, A., Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP and oxidative stress in patients with type 2 diabetes. Ann Nutr Metab 63 (2013), 1–9.
23. [23] Ostadrahimi, A., Taghizadeh, A., Mobasseri, M., Farrin, N., Payahoo, L., Ghheshlaghi, Z.B., et al. Effect of probiotic fermented Milk (Kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Iran J Public Health 44 (2015), 228–237.
24. [24] Andreasen, A.S., Larsen, N., Pedersen-Skovsgaard, T., Berg, R.M., Moller, K., Svendsen, K.D., et al. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr 104 (2010), 1831–1838.
25. [25] Nazaimoon, W.M.W., Isa, S.H.M., Mohamad, W.B.W., Khir, A.S., Kamaruddin, N.A., Kamarul, I.M., et al. Prevalence of diabetes in Malaysia and usefulness of HbA1c as a diagnostic criterion. Diabet Med, 2013, 1–4.
26. [26] Stratton, I.M., Adler, A.I., Andrew, H., Neil, W., Matthews, D.R., Manley, S.E., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): a prospective observational study. Br Med J 321 (2000), 405–412.
27. [27] Soranzo, N., Genetic determinants of variability in glycated hemoglobin (HbA1c) in humans: review of recent progress and prospects for use in diabetes care. Curr Diab Rep 11 (2011), 562–569.
28. [28] Noordzij, M., Tripepi, G., Dekker, F.W., Zocalli, C., Tanck, M.W., Jager, K.J., Sample size calculations: basic principles and common pitfalls. Nephrol Dial Transplant 24 (2010), 1388–1393.
29. [29] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycemia in Type 2 diabetes: a patient-centered approach. Diabetes Care 35 (2012), 1364–1379.
30. [30] Alsayadi, M., Jawfi, Y.A., Belarbi, M., Soualem-Mami, Z., Merzouk, H., Sari, D.C., et al. Evaluation of anti hyperglycemia and anti hyperlipidemic activities of water kefir as probiotic on streptozotocin-induced diabetic wistar rats. J Diabetes Mellitus 4 (2014), 85–95.
31. [31] Stenman, L.K., Waget, A., Garret, C., Klopp, P., Burcelin, R., Lahtinen, S., Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. Beneficial Microbes 5 (2014), 437–445.
32. [32] Yun, S.I., Park, H.O., Kang, J.H., Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. J Appl Microbiol 107 (2009), 1681–1686.
33. [33] Andersson, U., Branning, C., Ahrne, S., Molin, G., Alenfall, J., Onning, G., et al. Probiotics lower plasma glucose in the high-fat fed C57BL/6J mouse. Beneficial Microbes 1 (2010), 189–196.
34. [34] Dai, C., Zhen, C.-Q., Meng, F.J., Zhou, Z., Sang, L.-X., Jiang, M., VSL#3 probiotic exerts the anti inflammatory activity via P13k/Akt and NF-kB pathway in rat model of Dss-induced colitis. Mol Cell Biochem 374 (2013), 1–11.
35. [35] Valladares, R., Sankar, D., Li, N., Williams, E., Lai, K.-K., Abdelgeliel, A.S., et al. Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS One 5 (2010), 1–9.
36. [36] Henriksen, E.J., Diamond-Stanic, M.K., Marchionne, E.M., Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radical Biol Med 51 (2011), 993–999.
37. [37] Faghihi, T., Radfar, M., Barmal, M., Amini, P., Qorabani, M., Abdollahi, M., et al. A randomized, placebo controlled trial of selenium supplementation in patients with type2 diabtes: effect on glucose homeostasis, oxidative stress and lipid profile. Am J Ther 21 (2014), 491–495.
38. [38] Al-Rawi, N.H., Oxidative stress, antioxidant status and lipid profile in the saliva of type 2 diabetics. Diab Vasc Dis Res 8 (2011), 22–28.
39. [39] Zhang, Y., Du, R., Wang, L., Zhang, H., The antioxidative effects of probiotic Lactobacillus casei Zhang on the hyperlipidemic rats. Euro Food Res Technol 231 (2010), 151–158.
40. [40] Harisa, G.I., Taha, E.I., Khalil, A.F., Salem, M.M., Oral administration of Lactobacillus acidophilus restores nitric oxide level in diabetic rats. Aust J Basic Appl Sci 3 (2009), 2963–2969.
41. [41] Marteau, P., Evidence of probiotic strain specificity makes extrapolation of results impossible from a strain to another, even from the same species. Ann Gastroentol Hepatol, 2011, 1–3.
42. [42] Nguyen, T.D.T., Kang, J.H., Lee, M.S., Characterization of Lactobacillus plantarum PH04, a potential probiotic bacterium with cholesterol-lowering effects. Int J Food Microbiol 113 (2007), 358–361.
43. [43] Ranasinghe, J., Silva, S., Herath, N., Changes of serum lipids and protein during probiotics feeding and its exposure. Int J Sci Res Publ, 3, 2013.
44. [44] Wollowski, I., Rechkemmer, G., Pool-Zobel, B.L., Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 73 (2001), 451s–455s.
45. [45] Abd El-Gawad, I.A., El-Sayed, E.M., Hafez, S.A., El-Zeini, H.M., Saleh, F.A., The hypocholesterolaemic effect of milk yoghurt and soy-yoghurt containing bifidobacteria in rats fed on a cholesterol-enriched diet. Int Dairy J 15 (2005), 37–44.
46. [46] Myllyluoma, E., Veijola, L., Ahlroos, T., Tynkkynen, S., Kankuri, E., Vapaatalo, H., et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy – a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 21 (2005), 1263–1272.
47. [47] Noto, H., Goto, A., Tsujimoto, T., Noda, M., Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 7 (2012), 1–9.
48. [48] Button, K.S., Ioannidis, J.P., Mokrysz, C., Nosek, B.A., Flint, J., Robinson, E.S.J., et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 14 (2013), 365–376.
49. [49] Schulz, K.F., Grimes, D.A., Allocation concealment in randomised trials: defending against deciphering. Lancet 359 (2002), 614–618.